Inicio>>Ac-Ala-Leu-Cys-Asp-Asp-Pro-Arg-Val-Asp-Arg-Trp-Tyr-Cys-Gln-Phe-Val-Glu-Gly-NH₂

Ac-Ala-Leu-Cys-Asp-Asp-Pro-Arg-Val-Asp-Arg-Trp-Tyr-Cys-Gln-Phe-Val-Glu-Gly-NH₂

Catalog No.GA20473

The potent anticoagulant E-76, Acetyl-ALCDDPRVDRWYCQFVEG-amide, is an inhibitor of coagulation factor VIIa. It has been suggested that E-76 works by binding to an exosite on the factor VIIa protease domain, and non-competitively inhibits activation of factor X and amidolytic activity. E-76 has a well defined structure in solution determined by NMR spectroscopy that is similar to the X-ray crystal structure when complexed with factor VIIa and represents a new framework for the development of inhibitors for serine proteases.

Products are for research use only. Not for human use. We do not sell to patients.

Ac-Ala-Leu-Cys-Asp-Asp-Pro-Arg-Val-Asp-Arg-Trp-Tyr-Cys-Gln-Phe-Val-Glu-Gly-NH₂ Chemical Structure

Cas No.: 1926163-13-4

Tamaño Precio Disponibilidad Cantidad
1mg
802,00 $
Disponible
5mg
3.204,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The potent anticoagulant E-76, Acetyl-ALCDDPRVDRWYCQFVEG-amide, is an inhibitor of coagulation factor VIIa. It has been suggested that E-76 works by binding to an exosite on the factor VIIa protease domain, and non-competitively inhibits activation of

Reseñas

Review for Ac-Ala-Leu-Cys-Asp-Asp-Pro-Arg-Val-Asp-Arg-Trp-Tyr-Cys-Gln-Phe-Val-Glu-Gly-NH₂

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ac-Ala-Leu-Cys-Asp-Asp-Pro-Arg-Val-Asp-Arg-Trp-Tyr-Cys-Gln-Phe-Val-Glu-Gly-NH₂

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.